Beiersdorf Aktiengesellschaft Q4 Earnings Call Highlights

Beiersdorf Aktiengesellschaft (ETR:BEI) absorption said the institution delivered “stable” full-year 2025 results successful a hard operating backdrop, portion outlining steps to reconstruct momentum astatine its largest brand, NIVEA, and reaffirming concern successful innovation and semipermanent growth.

Executives opened the telephone by addressing volatility successful the Middle East, saying worker information was the apical precedence and that it was excessively aboriginal to measure immoderate imaginable concern impact.

→ The Head Fake: Buying the Chinese Stocks Post-Ruling Dip

Management described 2025 arsenic a twelvemonth marked by economical and geopolitical uncertainty, shifting user behaviour and commercialized disruptions. The planetary skincare marketplace slowed materially, decelerating from mid-single-digit maturation successful 2024 to astir 1.5% to 2% successful 2025, with emerging markets and Eastern Europe peculiarly affected. Pricing besides normalized aft earlier inflation-driven increases, and consumers became “more cautious and progressively selective” successful their routines.

Despite the slowdown, Beiersdorf said it maintained its presumption arsenic the “best performing skincare institution globally” for the 3rd twelvemonth successful a row. The institution reported that its full skincare concern grew 3.7% organically, intelligibly up of the market.

• NIVEA: 0.9% integrated income growth, impacted by weaker marketplace dynamics, a repositioning successful China, and innovation launches weighted toward the 2nd half.

• Derma (Eucerin and Aquaphor): double-digit maturation for the 5th consecutive year.

• La Prairie: integrated income down 4.5% for the year, with sequential betterment but continued volatility successful luxury.

• Tesa: integrated maturation of 1.8%, supported by electronics.

→ MarketBeat Week successful Review – 02/23 - 02/27

Beiersdorf highlighted Derma arsenic its standout performer. Net income successful the conception reached a grounds EUR 1.5 billion, approaching 20% of user nett sales, supported by marketplace stock gains adjacent arsenic the broader marketplace grew astatine debased single-digit rates. In the 4th quarter, Derma grew astir 10% contempt a pugnacious examination versus the anterior year’s Epicelline launch.

Growth was described arsenic broad-based crossed regions:

• Europe: 8.3% integrated growth, with Epicelline continuing to thrust results.

• North America: astir 9% growth, driven by look attraction and Radiant Tone (Thiamidol successful the U.S.).

• Emerging markets: 16.3% growth, with Thailand, Mexico and Brazil named arsenic cardinal drivers; India, home China and Japan were cited arsenic “white spaces” for expansion.

→ Home Depot & Lowe’s: Buying the Earnings Dip